Judge Hacks Away At Allergan's Restasis Patents

Law360, New York (October 16, 2017, 6:11 PM EDT) -- A federal judge ruled Monday that claims in several patents covering Allergan PLC’s dry-eye drug Restasis are invalid, dealing a blow to the drugmaker just weeks after it transferred the patents to a Native American tribe in an effort to shield them from review at the Patent Trial and Appeal Board.

The ruling is a significant step in allowing generics makers to sell their own versions of Allergan's Restasis, which generated about $1.5 billion in revenue last year. (AP) Senior U.S. Circuit Judge William Bryson issued his ruling following a recent bench trial in the Eastern District of Texas, where Allergan...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS